Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma

References

• Nael A, Walavalkar V, Wu W, et al. CD4-positive T-cell primary central nervous system lymphoma in an HIV positive patient. Am J Clin Pathol. 2016;145(2):258–265. doi:10.1093/ajcp/aqv087
   PubMed Web of Science ®Google Scholar
• Epeldegui M, Vendrame E, Martínez-Maza O. HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res. 2010;48(1–3):72–83. doi:10.1007/s12026-010-8168-8
   PubMed Web of Science ®Google Scholar
• Linke-Serinsoez E, Fend F, Quintanilla-Martinez L, editors. Human Immunodeficiency Virus (HIV) and Epstein-Barr Virus (EBV) Related Lymphomas, Pathology View Point. Seminars in Diagnostic Pathology. Elsevier; 2017.
   Google Scholar
• Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20(12):1645–1654.
   PubMed Web of Science ®Google Scholar
• van Leeuwen MT, Vajdic CM, Middleton MG, et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS. 2009;23(16):2183.
   PubMed Web of Science ®Google Scholar
• Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313.
   PubMedGoogle Scholar
• Yang J, Wang P, Lv Z-B, et al. AIDS-related non-Hodgkin lymphoma: imaging feature analysis of 27 cases and correlation with pathologic findings. Asian Pac J Cancer Prev. 2014;15(18):7769–7773. doi:10.7314/APJCP.2014.15.18.7769
   PubMedGoogle Scholar
• Arvey A, Ojesina A, Pedamallu CS, et al. The tumor virus landscape of AIDS-related lymphomas. Blood. 2015;125:11–59.
   Web of Science ®Google Scholar
• Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis. 2010;51(8):957–962. doi:10.1086/656416
   PubMed Web of Science ®Google Scholar
• Meister A, Hentrich M, Wyen C, Hübel K. Malignant lymphoma in the HIV‐positive patient. Eur J Haematol. 2018;101(1):119–126. doi:10.1111/ejh.13082
   PubMed Web of Science ®Google Scholar
• Li MF, Hsiao CH, Chen YL, et al. Human herpesvirus 8‐associated lymphoma mimicking cutaneous anaplastic large T‐cell lymphoma in a patient with human immunodeficiency virus infection. J Cutan Pathol. 2012;39(2):274–278. doi:10.1111/j.1600-0560.2011.01814.x
   PubMed Web of Science ®Google Scholar
• Carbone A, Vaccher E, Gloghini A, et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol. 2014;11(4):223. doi:10.1038/nrclinonc.2014.31
   PubMed Web of Science ®Google Scholar
• Garg H, Joshi A. Host and viral factors in HIV-mediated bystander apoptosis. Viruses. 2017;9(8):237. doi:10.3390/v9080237
   PubMed Web of Science ®Google Scholar
• Garg H, Mohl J, Joshi A. HIV-1 induced bystander apoptosis. Viruses. 2012;4(11):3020–3043. doi:10.3390/v4113020
   PubMed Web of Science ®Google Scholar
• Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science. 1998;280(5371):1884–1888. doi:10.1126/science.280.5371.1884
   PubMed Web of Science ®Google Scholar
• Castedo M, Ferri KF, Blanco J, et al. Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/Fkbp12-Rapamycin–associated protein–mediated P53 phosphorylation. J Exper Med. 2001;194(8):1097–1110.
   PubMed Web of Science ®Google Scholar
• Kim ES, Ackermann C, Tóth I, et al. Down‐regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression. J Leukoc Biol. 2017;101(5):1263–1271. doi:10.1189/jlb.5A0816-346R
   PubMed Web of Science ®Google Scholar
• Epeldegui M, Thapa DR, De La Cruz J, Kitchen S, Zack JA, Martínez-Maza O. CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One. 2010;5(7):e11448. doi:10.1371/journal.pone.0011448
   PubMed Web of Science ®Google Scholar
• Shen X, Tomaras GD. Alterations of the B-cell response by HIV-1 replication. Curr HIV/AIDS Rep. 2011;8(1):23–30. doi:10.1007/s11904-010-0064-2
   PubMedGoogle Scholar
• Epeldegui M, Magpantay L, Guo Y, et al. A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma. AIDS. 2018;32(7):945–954.
   PubMed Web of Science ®Google Scholar
• Vendrame E, Hussain SK, Breen EC, et al. Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev. 2014;23(2):343–349. doi:10.1158/1055-9965.EPI-13-0714
   PubMed Web of Science ®Google Scholar
• Nolen BM, Breen EC, Bream JH, et al. Circulating mediators of inflammation and immune activation in AIDS-related non-Hodgkin lymphoma. PLoS One. 2014;9(6):e99144. doi:10.1371/journal.pone.0099144
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Med. 2006;12(12):1365. doi:10.1038/nm1511
   PubMed Web of Science ®Google Scholar
• Koning FA, Otto SA, Hazenberg MD, et al. Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol. 2005;175(9):6117–6122. doi:10.4049/jimmunol.175.9.6117
   PubMed Web of Science ®Google Scholar
• Fiorentini S, Marini E, Caracciolo S, Caruso A. Functions of the HIV-1 matrix protein p17. Microbiologica. 2006;29(1):1–10.
   PubMed Web of Science ®Google Scholar
• He B, Qiao X, Klasse PJ, et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol. 2006;176(7):3931–3941. doi:10.4049/jimmunol.176.7.3931
   PubMed Web of Science ®Google Scholar
• Birendra K, Afzal MZ, Wentland KA, et al. Spontaneous regression of refractory diffuse large B-cell lymphoma with improvement in immune status with ART in a patient with HIV: a case report and literature review. Am J Case Rep. 2015;16:347. doi:10.12659/AJCR.892883
   PubMedGoogle Scholar
• Min H, Yang J, Wang S, et al. Remission of HIV-related naïve and high-risk Burkitt’s lymphoma treated by autologous stem cell transplantation plus cART. Stem Cell Res Ther. 2018;9:1–6. doi:10.1186/s13287-018-1089-5
   PubMed Web of Science ®Google Scholar
• Khwaja J, Burns JE, Ahmed N, Cwynarski K. HIV-associated lymphoma—Advances in clinical management. Ann Lymphoma. 2021;5. doi:10.21037/aol-21-16
   Google Scholar
• Xicoy B, Ribera J-M, Mate J-L, et al. Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. Leuk Lymphoma. 2010;51(11):2063–2069. doi:10.3109/10428194.2010.520772
   PubMed Web of Science ®Google Scholar
• Cesarman E. Pathology of lymphoma in HIV. Curr Opin Oncol. 2013;25(5):487. doi:10.1097/01.cco.0000432525.70099.a4
   PubMed Web of Science ®Google Scholar
• Chadburn A, Abdul-Nabi AM, Teruya BS, Lo AA. Lymphoid proliferations associated with human immunodeficiency virus infection. Arch Pathol Lab Med. 2013;137(3):360–370. doi:10.5858/arpa.2012-0095-RA
   PubMed Web of Science ®Google Scholar
• Baptista MJ, Tapia G, Morgades M, et al. Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;60:1–5.
   PubMed Web of Science ®Google Scholar
• Ota Y, Hishima T, Mochizuki M, et al. Classification of AIDS‐related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas. Cancer Med. 2014;3(1):143–153. doi:10.1002/cam4.178
   PubMed Web of Science ®Google Scholar
• Conconi A, Zucca E, Margiotta‐Casaluci G, et al. Population‐based outcome analysis of diffuse large B‐cell lymphoma in people living with HIV infection and competent individuals. Hematol Oncol. 2018;36(5):757–764. doi:10.1002/hon.2536
   PubMed Web of Science ®Google Scholar
• Baptista MJ, Garcia O, Morgades M, et al. HIV-infection impact on clinicalâ–“biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. Aids. 2015;29(7):811–818. doi:10.1097/QAD.0000000000000624
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the HAART era. J Acquir Immune Defic Syndr. 2010;54(1):78. doi:10.1097/01.qai.0000371677.48743.8d
   PubMed Web of Science ®Google Scholar
• Vajpayee N, Thakral C, Gopaluni S, Newman N, Gajra A. Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: a clinicopathological study. Leuk Res. 2012;36(11):1403–1409. doi:10.1016/j.leukres.2012.07.016
   PubMed Web of Science ®Google Scholar
• Browne SH, Diaz-Perez JA, Preziosi M, et al. mTOR activity in AIDS-related diffuse large B-cell lymphoma. PLoS One. 2017;12(2):e0170771. doi:10.1371/journal.pone.0170771
   PubMed Web of Science ®Google Scholar
• Hentrich M, Barta SK. HIV-Associated Hematological Malignancies. Springer; 2016.
   Google Scholar
• Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood. 2003;102(5):1833–1841. doi:10.1182/blood-2002-11-3606
   PubMed Web of Science ®Google Scholar
• Cotterman R, Jin VX, Krig SR, et al. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res. 2008;68(23):9654–9662. doi:10.1158/0008-5472.CAN-08-1961
   PubMed Web of Science ®Google Scholar
• Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200. doi:10.1200/JCO.2010.30.0368
   PubMed Web of Science ®Google Scholar
• Chao C, Silverberg MJ, Xu L, et al. A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection. Clin Cancer Res. 2015;21(6):1429–1437. doi:10.1158/1078-0432.CCR-14-2083
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A. The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood. 2013;122(3):459–460. doi:10.1182/blood-2013-05-502799
   PubMedGoogle Scholar
• Besson C, Lancar R, Prevot S, et al. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. Aids. 2017;31(18):2493–2501. doi:10.1097/QAD.0000000000001652
   PubMed Web of Science ®Google Scholar
• Rangel J, Novoa R, Morrison C, Frank D, Kovarik C. Fistulizing Epstein–Barr virus‐positive plasmablastic lymphoma in an HIV‐positive man. Br J Dermatol. 2016;174(2):398–401. doi:10.1111/bjd.14089
   PubMed Web of Science ®Google Scholar
• Wang D, Zheng Y, Zeng D, et al. Clinicopathologic characteristics of HIV/AIDS-related plasmablastic lymphoma. Int J STD/AIDS. 2017;28(4):380–388.
   PubMed Web of Science ®Google Scholar
• Wang B, Song B, Oster C, Cao J, Raza A, Wang J. Coexistence of intestinal Kaposi sarcoma and plasmablastic lymphoma in an HIV/AIDS patient: case report and review of the literature. J Gastrointest Oncol. 2016;7(1):88.
   Google Scholar
• Castillo J, Pantanowitz L, Dezube BJ. HIV‐associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83(10):804–809. doi:10.1002/ajh.21250
   PubMed Web of Science ®Google Scholar
• Lorsbach RB, Hsi ED, Dogan A, Fend F. Plasma cell myeloma and related neoplasms. Am J Clin Pathol. 2011;136(2):168–182. doi:10.1309/AJCPENJ68FFBRIYB
   PubMed Web of Science ®Google Scholar
• Mani SSR, Kodiatte T, Jagannati M. A rare presentation of plasmablastic lymphoma as cutaneous nodules in an immunocompromised patient. Int J STD & AIDS. 2017;28(6):623–625.
   PubMed Web of Science ®Google Scholar
• Noy A, Kaplan L, Lee J, Cesarman E, Tam W. Modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt (BL)(AMC 048) shows efficacy and tolerability, and predictive potential of IRF4/MUM1 expression. Infect Agent Cancer. 2012;7(1):14. doi:10.1186/1750-9378-7-S1-O14
   PubMedGoogle Scholar
• Bibas M, Castillo JJ. Current knowledge on HIV-associated plasmablastic lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014064. doi:10.4084/mjhid.2014.064
   PubMedGoogle Scholar
• Brandsma D, Bromberg JE. Primary CNS lymphoma in HIV infection. Handb Clin Neurol. 2018;152:177–186.
   PubMedGoogle Scholar
• Shiels MS, Pfeiffer RM, Hall HI, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980–2007. JAMA. 2011;305(14):1450–1459. doi:10.1001/jama.2011.396
   PubMed Web of Science ®Google Scholar
• Rios A. HIV-related hematological malignancies: a concise review. Clin Lymphoma Myeloma Leuk. 2014;14:96–103. doi:10.1016/j.clml.2014.06.020
   Web of Science ®Google Scholar
• Sasakawa A, Hirase C, Yamaguchi T, et al. Interleukin-8 in the pathogenesis of primary central nervous system lymphoma in association with HIV infection. Hematology. 2012;17(3):144–150. doi:10.1179/102453312X13376952196377
   PubMed Web of Science ®Google Scholar
• Deckert M, Engert A, Brück W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25(12):1797. doi:10.1038/leu.2011.169
   PubMed Web of Science ®Google Scholar
• Kimani SM, Painschab MS, Horner M-J, et al. Epidemiology of haematological malignancies in people living with HIV. Lancet HIV. 2020;7(9):e641–e51. doi:10.1016/S2352-3018(20)30118-1
   PubMed Web of Science ®Google Scholar
• Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116. doi:10.1038/nature11378
   PubMed Web of Science ®Google Scholar
• Alves de Almeida M, Nesi Cardoso Migliano Porto J, de Brito Lyra AC, et al. First report of AIDS-related Burkitt’s lymphoma presenting as bilateral orbital masses. Case Rep Infect Dis. 2016;2016. doi:10.1155/2016/6469528
   PubMedGoogle Scholar
• Baek D-Y, Heo D-H, Oh S-M, et al. A Case of Jejunal Intussusception caused by Burkitt Lymphoma in an Acquired Immunodeficiency Syndrome Patient. Infect Chemother. 2018;50(1):51. doi:10.3947/ic.2018.50.1.51
   PubMed Web of Science ®Google Scholar
• Noy A, Lee JY, Cesarman E, et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015;126:1–6.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Little RF, Wilson WH. Update on Burkitt lymphoma. Hematol Oncol Clin. 2016;30(6):1333–1343. doi:10.1016/j.hoc.2016.07.009
   PubMed Web of Science ®Google Scholar
• Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl j Med. 2006;354(23):2419–2430. doi:10.1056/NEJMoa055351
   PubMed Web of Science ®Google Scholar
• Bibas M, Antinori A. EBV and HIV-related lymphoma. Mediterr J Hematol Infect Dis. 2009;1(2). doi:10.4084/MJHID.2009.032
   PubMedGoogle Scholar
• Krishnan A, Zaia JA. HIV-associated non-Hodgkin lymphoma: viral origins and therapeutic options. Am Soc Hematol Educ Program Book. 2014;2014(1):584–589. doi:10.1182/asheducation-2014.1.584
   PubMed Web of Science ®Google Scholar
• Alderuccio JP, Olszewski AJ, Evens AM, et al. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv. 2021;5(14):2852–2862. doi:10.1182/bloodadvances.2021004458
   PubMed Web of Science ®Google Scholar
• Hashmi H, Murray D, Al-Quran S, Tse W. Primary effusion lymphoma without an effusion: a rare case of solid extracavitary variant of primary effusion lymphoma in an HIV-positive patient. Case Rep Hematol. 2018;2018:1–5. doi:10.1155/2018/9368451
   Web of Science ®Google Scholar
• Scott MJ, Chihada Alhariri B, Farghaly H, Perez R, Arnold FW. Castleman’s disease and primary effusion lymphoma in a HIV-positive patient. Int J STD & AIDS. 2014;25(6):455–457.
   PubMed Web of Science ®Google Scholar
• Okada S, Goto H, Yotsumoto M. Current status of treatment for primary effusion lymphoma. Intract Rare Dis Res. 2014;3(3):65–74. doi:10.5582/irdr.2014.01010
   PubMedGoogle Scholar